Hence, as in other clinical trials when using for example mitogen‐activated protein kinase kinase 1 or rapidly accelerated fibrosarcoma inhibitors, it would be important for JAK1/2 targeting clinical trials to stratify for the K‐RAS mutational status. This evidence concerns the gene KRAS and fibrosarcoma.